These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22116771)

  • 1. Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies.
    Burkhardt JE; Pandher K; Solter PF; Troth SP; Boyce RW; Zabka TS; Ennulat D
    Toxicol Pathol; 2011 Dec; 39(7):1129-37. PubMed ID: 22116771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topic of histopathology blinding in nonclinical safety biomarker qualification studies.
    Burkhardt JE; Ennulat D; Pandher K; Solter PF; Troth SP; Boyce RW; Zabka TS
    Toxicol Pathol; 2010 Jun; 38(4):666-7. PubMed ID: 20530250
    [No Abstract]   [Full Text] [Related]  

  • 3. Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.
    Perry R; Farris G; Bienvenu JG; Dean C; Foley G; Mahrt C; Short B;
    Toxicol Pathol; 2013; 41(8):1159-69. PubMed ID: 23531793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies.
    Bolon B; Barale-Thomas E; Bradley A; Ettlin RA; Franchi CA; George C; Giusti AM; Hall R; Jacobsen M; Konishi Y; Ledieu D; Morton D; Park JH; Scudamore CL; Tsuda H; Vijayasarathi SK; Wijnands MV
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):187-95. PubMed ID: 20724123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response letter from Clinical Pathology Interest Group of the Society of Toxicologic Pathology (STP) for manuscript entitled International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies by Bolon et al.
    Tripathi NK; Schultze AE; Pearson RC; Everds NE; Elliott GS; Ramaiah L; Wells MY; Latimer KS; Walter GL; Katavolos P; Collins ND; Tarrant J; Walker DB; Topper MJ; Jordan HL; O'Rourke LG; Guilpin VB; Brockus CW; Wilcox AL; Clemo FA; Smith GS; Reagan WJ; McCartney JE
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):39. PubMed ID: 21676604
    [No Abstract]   [Full Text] [Related]  

  • 6. STP position paper: Recommended practices for sampling and processing the nervous system (brain, spinal cord, nerve, and eye) during nonclinical general toxicity studies.
    Bolon B; Garman RH; Pardo ID; Jensen K; Sills RC; Roulois A; Radovsky A; Bradley A; Andrews-Jones L; Butt M; Gumprecht L
    Toxicol Pathol; 2013; 41(7):1028-48. PubMed ID: 23475559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Forum Opinion Piece: Blinding and Binning in Histopathology Methods in the Biomarker Qualification Process.
    Rouse R
    Toxicol Pathol; 2015 Aug; 43(6):757-9. PubMed ID: 25755101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
    Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
    Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best practices for clinical pathology testing in carcinogenicity studies.
    Young JK; Hall RL; O'Brien P; Strauss V; Vahle JL
    Toxicol Pathol; 2011 Feb; 39(2):429-34. PubMed ID: 21297067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opinion on Current Use of Non-Blinded Versus Blinded Histopathologic Evaluation in Animal Toxicity Studies.
    Bolon B; Caverly Rae JM; Colman K; Francke S; Jensen K; Keane K; McInnes EF; Nakano-Ito K; Perry R; Polack E; Regan KS; Romeike A; Young JK; Galbreath EJ
    Toxicol Pathol; 2020 Jun; 48(4):549-559. PubMed ID: 32347786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Society of toxicologic pathology position paper: review series: assessment of circulating hormones in nonclinical toxicity studies: general concepts and considerations.
    Stanislaus D; Andersson H; Chapin R; Creasy D; Ferguson D; Gilbert M; Rosol TJ; Boyce RW; Wood CE
    Toxicol Pathol; 2012 Aug; 40(6):943-50. PubMed ID: 22569585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory forum opinion piece: blind reading of histopathology slides in general toxicology studies.
    Neef N; Nikula KJ; Francke-Carroll S; Boone L
    Toxicol Pathol; 2012 Jun; 40(4):697-9. PubMed ID: 22407309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Overview on the Considerations for the Planning of Nonclinical Necropsies for Medical Device Studies.
    Stanley JRL; Keating JH; San Souci KJ
    Toxicol Pathol; 2019 Apr; 47(3):213-220. PubMed ID: 30727861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.
    Tomlinson L; Ramaiah L; Tripathi NK; Barlow VG; Vitsky A; Poitout-Belissent FM; Bounous DI; Ennulat D
    Toxicol Pathol; 2016 Feb; 44(2):163-72. PubMed ID: 26879687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Society of Toxicologic Pathology position paper on pathology image data: compliance with 21 CFR Parts 58 and 11.
    Tuomari DL; Kemp RK; Sellers R; Yarrington JT; Geoly FJ; Fouillet XL; Dybdal N; Perry R;
    Toxicol Pathol; 2007 Apr; 35(3):450-5. PubMed ID: 17474067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Forum Opinion Piece*: Effective Brain Trimming for Regulatory-type Nonclinical Toxicity Studies.
    Bolon B
    Toxicol Pathol; 2018 Feb; 46(2):115-120. PubMed ID: 29278994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STP debate on the desirability of an international mechanism for recognizing qualified toxicologic pathologists.
    Bolon B; Ochoa R; Mann P
    Toxicol Pathol; 2009 Dec; 37(7):992-6. PubMed ID: 19820139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the study pathologist.
    Weber K
    Toxicol Pathol; 2014 Jan; 42(1):276-7. PubMed ID: 24334675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualification of cardiac troponins for nonclinical use: a regulatory perspective.
    Hausner EA; Hicks KA; Leighton JK; Szarfman A; Thompson AM; Harlow P
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):108-14. PubMed ID: 23876748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.